The addition of a short-term, flat dose of bevacizumab (Avastin) to pembrolizumab (Keytruda) was found to enhance the response to anti–PD-1 therapy in the absence of chemotherapy for patients with platinum-resistant epithelial ovarian cancer, according to results from the phase 1 PEMBOV trial (NCT03596281) presented during the 2021 SITC Annual Meeting.1
Results from the study showed that among the 19 patients enrolled, the combination yielded an overall response rate (ORR) of 26%; this was comprised of 1 complete response (CR; 5%) and 4 partial responses (PRs; 21%). Additionally, the disease control rate (DCR) with the doublet was 79%.
For patients with platinum-resistant ovarian cancer, there is an unmet medical need for more efficacious treatment options. Previously, the phase 3 AURELIA trial (NCT00976911) examined the combination of chemotherapy and bevacizumab in platinum-resistant patients who were bevacizumab naïve and had received a maximum of 2 prior treatment regimens. Results showed that the median progression-free survival (PFS) was 3.4 months in those treated with chemotherapy vs 6.7 months in those who received the combination. Moreover, the ORRs reported in each group were 11.8% and 27.3% respectively.2Bevacizumab monotherapy has been shown to induce a median PFS of 4.4 months and an ORR of 15.9% in this patient population.3 Anti–PD-1/anti–PD-L1 monotherapies have been shown to elicit ORRs ranging from 3.7% to 15.0%, and a median PFS ranging from 1.9 months to 3.5 months. The addition of chemotherapy to these agents appears to slightly improve outcomes, with ORRs ranging from 13.3% to 23.0%, and a median PFS ranging from 3.7 months to 8.1 months.4-8
Prior phase 2 trials have also examined the combination of anti–PD-L1 therapy and PARP inhibitors, a regimen that has been shown to elicit an ORR of 14.0% and a median PFS of 3.9 months,9 as well as anti–PD-L1 therapy, PARP inhibition, and bevacizumab, a triplet which yielded an ORR of 28.0% and a median PFS of 4.1 months.10Additionally, phase 1b/2 combinations trials have previously examined pembrolizumab in combination with bevacizumab and chemotherapy. When pembrolizumab and bevacizumab were paired with pegylated liposomal doxorubicin (PLD), the regimen yielded an ORR of 32.0%.11 When the 2 agents were combined with cyclophosphamide, they induced an ORR of 43.3% and a median PFS of 7.6 months.12
Prior phase 2 clinical trials have investigated the combination of an anti–PD-1 blockade plus an anti–CTLA-4 blockade. Results from these trials have showed that this approach can produce an ORR of 31.4% and a median PFS of 3.9 months.13The PEMBOV study enrolled patients with platinum-resistant epithelial ovarian cancer. There was no limit to the number of previous treatments patients could have received, and prior treatment with bevacizumab was permitted.
The study was comprised of 2 cohorts. Patients in cohort A received pembrolizumab plus PLD, and those in cohort B were given pembrolizumab plus bevacizumab. Here, investigators reported data from cohort B of the study.14Patients enrolled to cohort B received 200 mg of pembrolizumab once every 3 weeks (q3W) until disease progression, unacceptable toxicity, or withdrawal of consent, and 400 mg of bevacizumab q3w for 6 cycles.The primary end point of the study was best overall response (BOR) per RECIST v1.1 criteria, and duration of response (DOR). Secondary end points included safety and tolerability, and key exploratory objectives were to examine PD-L1 status and the pharmacokinetics of bevacizumab.
- Michels J, Frenel J-S, Genestie C, et al. Pembrolizumab and bevacizumab in platinum resistant epithelial ovarian cancer patients. Presented at: 2021 SITC Annual Meeting; November 10-14, 2021; Washington DC. Abstract 355.
- Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302-1308. doi:10.1200/JCO.2013.51.4489
- Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007;25(33):5180-6. doi:10.1200/JCO.2007.12.0782
- Hamanishi J, Mandai M, Ikeda T, et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2015;33(34):4015-4022. doi:10.1200/JCO.2015.62.3397
- Disis ML, Taylor MH, Kelly K, et al. Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial. JAMA Oncol. 2019;5(3):393-401. doi:10.1001/jamaoncol.2018.6258
- Matulonis UA, Shapira-Frommer R, Santin AD, et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann Oncol. 2019;30(7):1080-1087. doi:10.1093/annonc/mdz135
- Pujade-Lauraine E, Fujiwarab K, Ledermannc JA, et al. Avelumab alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant or refractory epithelial ovarian cancer: Primary and biomarker analysis of the phase III JAVELIN Ovarian 200 trial. Presented at: 50th Annual Meeting of the Society of Gynecologic Oncology; March 16-19, 2019. Honolulu, HI.
- Lee EK, Xiong N, Cheng S-C, et al. Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial. Gynecol Oncol. 2020;159(1):72-78. doi:10.1016/j.ygyno.2020.07.028
- Lampert EJ, Zimmer A, Padget M, et al. Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase II study. Clin Cancer Res. 2020;26(16):4268-4279. doi:10.1158/1078-0432.CCR-20-0056
- Freyer G, Floquet A, Tredan O, et al. 733P Bevacizumab (bev), olaparib (ola) and durvalumab (durva) in patients with recurrent advanced ovarian cancer (AOC): The GINECO BOLD study. Ann Oncol. 2021;32(5):S734-S735. doi:10.1016/j.annonc.2021.08.1176
- Michels J, Ghiringhelli F, Frenel J-S, et al. Pembrolizumab in combination with bevacizumab and pegylated liposomal doxorubicin in patients with platinum-resistant epithelial ovarian cancer. J Clin Oncol. 2021;39(15):5522. doi:10.1200/JCO.2021.39.15_suppl.5522
- Zsiros E, Lynam S, Attwood K, et al. Efficacy and safety of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of recurrent ovarian cancer: a phase 2 nonrandomized clinical trial. JAMA Oncol. 2021;7(1):78-85. doi:10.1001/jamaoncol.2020.5945
- Zamarin D, Burger RA, Sill MW, et al. Randomized phase II trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: an NRG oncology study. J Clin Oncol. 2020;38(16):1814-1823. doi:10.1200/JCO.19.02059
- Pembrolizumab in combination with bevacizumab and pegylated liposomal doxorubicin in patients with ovarian cancer (PEMBOV). ClinicalTrials.gov. Updated July 22, 2021. Accessed November 17, 2021.
Post a Comment